Tuesday, October 11, 2022 Daily Archives

Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia Coli

by

This webcast features: Sharon Bola, Global Product Manager, Process Chromatography, Bio-Rad Laboratories. With the increasing global demand for insulin product, there is a need to develop a more efficient and economical process for the production of recombinant insulin therapeutics. In this webcast, we will present an efficient downstream processing workflow for recombinant human insulin production using Escherichia Coli as the host system. Data will be presented for sample preparation and purification results of proinsulin and insulin. Size exclusion was identified…

October 11, 2022

BioProcess Insider State of the Industry – Live from Biotech Week Boston

by

Ukraine escalation, COVID drop off, cell and gene approvals, and sustainability efforts were the focus of the latest BioProcess Insider State of the Industry discussion at BPI Boston Frank Orlowski, Director of Business Development at Latham Biopharm Group, Miriam Monge, Head of Marketing Fluid Management Technologies at Sartorius, and Joseph Scott, Vice President, Supply Chain at Avid Bioservices, sat down with BioProcess Insider’s Dan Stanton to discuss the geopolitical issues affecting the biomanufacturing space. In front of a full crowd…

October 11, 2022

Forge Bio launches pDNA production to support gene therapy clients

by

Forge Biologics has launched plasmid DNA (pDNA) manufacturing services to support its AAV clients after closing a $90 million Series C funding round. Gene therapy contract development manufacturing organization (CDMO) Forge Bio completed a $90 million Series C financing round last month, which it said would be used to expand its technologies, manufacturing systems, and cell lines. Now, the firm has said that on the back of the Series C funding round and the US government’s investment of over $2…

October 11, 2022

Finding CHO cell lines for mAbs too slow, say researchers

by

Chinese hamster ovary cells may be the foundation of modern biopharmaceuticals but the process of finding high-producer clones is too labor intensive, according to new research. The study – published in the Journal of Bioscience and Bioengineering in March – examined how the biopharmaceutical industry is using CHO cells and identified clone selection as a remaining challenge for the industry “CHO cells are widely used for constructing expression systems to produce therapeutic proteins. However, the establishment of high-producer clones remains a laborious and…

October 11, 2022

BioNTech heads down under to build mRNA plant

by

BioNTech has entered into a partnership with the State of Victoria, Australia to construct a research and manufacturing center for mRNA-based products in Melbourne. According to the German biopharma company, the center will support “discovery to delivery” of messenger RNA (mRNA) vaccines and therapies. Additionally, as part of the collaboration, BioNTech will construct a BioNTainer facility for clinical scale manufacturing of mRNA-based products and candidates. A BioNTainer is a cleanroom built from six ISO sized containers and consisting of one…

October 11, 2022